C-kit receptor expression in acute leukemias - Association with patient and disease characteristics and with outcome

Leukemia Research

Volumn 28, Issue 4, 2004, Pages 373-378

  Tsao, Anne S ^a   Kantarjian, Hagop ^a   Thomas, Deborah ^a   Giles, Francis ^a   Cortes, Jorge ^a   Garcia Manero, Guillermo ^a   Huh, Yang ^a   Yang, Ying ^a   Shen, Yu ^a   Albitar, Maher ^a   Estey, Elihu ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphocytic leukemia (ALL); Acute myelogenous leukemia (AML); C kit; Martingale residual plots

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; IDARUBICIN; STEM CELL FACTOR RECEPTOR; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; CHROMOSOME ABERRATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA 1 CHROMOSOME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; TREATMENT OUTCOME;

EID: 10744227578     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.09.008     Document Type: Article

References (14)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics 2003. CA Cancer J. Clin. 53:2003;5-26.
2. Pui C.H., Evans W.E. Acute lymphoblastic leukemia. N Engl J Med. 339:1998;605-615.
3. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med. 341:1999;1051-1062.
4. Rosnet O., Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog. 4:1993;595-613.
5. Qiu F.H., Ray P., Brown K., Barker P.E., Jhanwar S., Ruddle F.H.et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family - oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J. 7:1988;1003-1011.
6. Yarden Y., Kuang W.J., Yang-Feng T., Coussens L., Munemitsu S., Dull T.J.et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6:1987;3341-3351.
7. Ogawa M., Matsuzaki Y., Nishikawa S., Hayashi S., Kunisada T., Sudo T.et al. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med. 174:1991;63-71.
8. Kanakura Y., Ikeda H., Kitayama H., Sugahara H., Furitsu T. Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells. Leuk Lymphoma. 10:1993;35-41.
9. Ashman L.K., Cambareri A.C., To L.B., Levinsky R.J., Juttner C.A. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood. 78:1991;30-37.
10. Kuriu A., Ikeda H., Kanakura Y., Griffin J.D., Druker B., Yagura H.et al. Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. Blood. 78:1991;2834-2840.
11. Commenges D., Rondeau V. Standardized Martingale residuals applied to grouped left truncated observations of dementia cases. Lifetime Data Anal. 6:2000;229-235.
12. Estey E.H., Thall P.F., Cortes J.E., Giles F.J., O'Brien S., Pierce S.A.et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 98:2001;3575-3583.
13. Ashman L.K., Roberts M.M., Gadd S.J., Cooper S.J., Juttner C.A. Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. Leuk Res. 12:1988;923-928.
14. Lauria F., Bagnara G.P., Rondelli D., Raspadori D., Strippoli P., Bonsi L.et al. Cytofluorimetric and functional analysis of c-kit receptor in acute leukemia. Leuk Lymphoma. 18:1995;451-455.